RxDoctor Payments Data

Jeffrey Evans, MD

Pulmonary Disease · Oxford, MSNPI 1053414326

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (57.2%), education and travel and lodging — rather than concentrated in one kind of arrangement. 50 manufacturers reported payments, led by Intuitive Surgical at 38.2% of the total. Reporting peaked in 2024 at $10,181 and has fallen 62.4% since, to $3,830 in 2025.

$20,890in general payments, 2019–2025

Across 564 payments — averaging $37.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$8K
  • GSK$2K
  • Inspire Medical Systems, Inc.$2K
  • Harmony Biosciences LLC$1K
  • Boehringer Ingelheim$988
  • Medical Device Business Services, Inc.$846
  • plus $6K from 44 others

What the payments were for

  • Travel & lodging$1,5848%
  • Food & beverage$11,95257%
  • Education$7,35435%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,890 in reported general payments places this provider in the 85th percentile of 101 pulmonary disease providers in Mississippi.

See all pulmonary disease providers in Mississippi

Medicare billing

Part B allowed, 2024
$182,876
Medicare patients
760
Services billed
1,930

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
WakixPitolisant Hcl13$198,135
Trelegy ElliptaFluticasone/Umeclidin/Vilanter240$195,868
Aralast NpAlpha-1-Proteinase Inhibitor12$126,117
Breztri AerosphereBudesonide/Glycopyr/Formoterol49$41,331
Breo ElliptaFluticasone/Vilanterol53$27,994
Spiriva RespimatTiotropium Bromide35$27,875
Stiolto RespimatTiotropium Br/Olodaterol Hcl43$25,571
SymbicortBudesonide/Formoterol Fumarate62$18,643
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr26$12,050
Spiriva HandihalerTiotropium Bromide13$9,447
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate52$8,895
Sildenafil Citrate11$7,847
Albuterol Sulfate HfaAlbuterol Sulfate182$6,963
Arnuity ElliptaFluticasone Furoate19$5,528
Ventolin HfaAlbuterol Sulfate59$4,565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$1,937$241,440338 claims
Harmony Biosciences LLCWakix$1,094$198,13513 claims
AstraZenecaBreztri Aerosphere, Symbicort$681$59,974111 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$988$53,44678 claims
MerckDulera$276$4,07213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 101 pulmonary disease providers in Mississippi.

Other pulmonary disease in Oxford

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →